Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/plasma--what is a useful tool in clinical studies of anti-angiogenic drugs?
Mross
K
K
Tumor Biology Center at the Albert Ludwigs University Freiburg, Germany.
Fuxius
S
S
Drevs
J
J
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D015415:Biomarkers / Q000032:analysis; D002199:Capillary Permeability; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008279:Magnetic Resonance Imaging; D012039:Regional Blood Flow; D014055:Tomography, Emission-Computed
D020533:Angiogenesis Inhibitors; D015415:Biomarkers